Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers - Trial NCT06361355
Access comprehensive clinical trial information for NCT06361355 through Pure Global AI's free database. This Phase 1 trial is sponsored by Taizhou Mabtech Pharmaceutical Co.,Ltd and is currently Recruiting. The study focuses on Healthy Volunteers. Target enrollment is 132 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Taizhou Mabtech Pharmaceutical Co.,Ltd
Timeline & Enrollment
Phase 1
Nov 02, 2023
Jun 01, 2024
Primary Outcome
Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time,Maximum Concentration of Denosumab
Summary
This is a randomized, double-blinded, parallel-controlled Phase I study of CMAB807
 administered by subcutaneous injection. This study will characterize the pharmacokinetic,
 pharmacodynamics, safety and immunogenicity of CMAB807 Post-change in Manufacturing Site,
 versus Prolia #Denosumab# in healthy male subjects after a single dose
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06361355
Non-Device Trial

